Skip to main content
. 2017 Apr;8(2):266–278. doi: 10.21037/jgo.2016.11.08

Figure 2.

Figure 2

66-y/o male with 10 cm unresectable HCC, BCLC stage C, that has invaded the inferior vena cava. (A) CT prior to Y-90 resin administration; (B) angiogram on day of Y-90 resin treatment; (C) CT following three Y-90 resin treatments that occurred in January, March, and July of 2010; small area of radiation necrosis at prior site of 10 cm tumor observed. Patient’s baseline AFP was 143,987 ng/mL and decreased to 113,200; 43,295; and 9.5 after the 1st, 2nd and 3rd Y-90 resin treatments, respectively. As of February 2016 the patient’s AFP is 13.2. HCC, hepatocellular carcinoma; BCLC, Barcelona clinic liver cancer; AFP, alpha-fetoprotein.